Literature DB >> 9014858

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis.

B S Verbeek1, T M Vroom, S S Adriaansen-Slot, A E Ottenhoff-Kalff, J G Geertzema, A Hennipman, G Rijksen.   

Abstract

In human breast cancer, c-Src activity is elevated compared to normal breast tissue. It is not yet known whether this increase in c-Src activity is accompanied by an increase in c-Src protein expression. In this study, c-Src activity and protein expression were determined in a series of human breast cancers and in normal breast tissue, using immune complex kinase assays and immunoblotting. As the heterogeneity of breast cancer is not taken into account in these biochemical experiments, immunohistochemistry was also used to distinguish between normal and malignant cells. In human breast cancers, the c-Src activity is increased 4- to 30-fold, compared with normal breast tissue. This enhanced activity is accompanied by an increase in c-Src protein expression, as shown by both immunoblotting and immunohistochemistry. Immunohistochemistry indicates that the majority of c-Src appears to be concentrated around the nucleus in malignant cells, whereas in normal cells, it is distributed more evenly in the cytoplasm. These data confirm that c-Src activity is increased in human breast cancer. In addition, this study provides strong immunohistochemical evidence that the c-Src protein is also overexpressed, enabling a distinction to be made between normal and malignant cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014858     DOI: 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  79 in total

Review 1.  Angiogenic signal during cardiac repair.

Authors:  Nilanjana Maulik
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

2.  Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling.

Authors:  Emma Sandilands; Bryan Serrels; David G McEwan; Jennifer P Morton; Juan Pablo Macagno; Kenneth McLeod; Craig Stevens; Valerie G Brunton; Wallace Y Langdon; Marcos Vidal; Owen J Sansom; Ivan Dikic; Simon Wilkinson; Margaret C Frame
Journal:  Nat Cell Biol       Date:  2011-12-04       Impact factor: 28.824

3.  Src kinase activation: A switched electrostatic network.

Authors:  Elif Ozkirimli; Carol Beth Post
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

Review 4.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

5.  Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion.

Authors:  Hiroshi Nozawa; Gina Howell; Shinsuke Suzuki; Qing Zhang; Yanjun Qi; Judith Klein-Seetharaman; Alan Wells; Jennifer R Grandis; Sufi M Thomas
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

6.  ZBP1 enhances cell polarity and reduces chemotaxis.

Authors:  Kyle Lapidus; Jeffrey Wyckoff; Ghassan Mouneimne; Mike Lorenz; Lillian Soon; John S Condeelis; Robert H Singer
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

Review 7.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

8.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.

Authors:  B Elsberger; R Fullerton; S Zino; F Jordan; T J Mitchell; V G Brunton; E A Mallon; P G Shiels; J Edwards
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

Review 10.  Triple-negative breast cancer.

Authors:  Reinaldo D Chacón; María V Costanzo
Journal:  Breast Cancer Res       Date:  2010-10-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.